A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer
Sponsor: Genentech, Inc.
Terminated
Based on data collected, the combination appeared to be poorly tolearated.
Other terminated trials from Genentech, Inc.
- Idiopathic Pulmonary Fibrosis · Phase PHASE2 · Jan 2026
- Non-small Cell Lung Cancer · Phase PHASE2 · Nov 2025
- Solid Tumour · Phase PHASE1 · Nov 2025
- Diffuse Large B-cell Lymphoma · Oct 2025
- Ulcerative Colitis · Phase PHASE2 · Jun 2025
More terminations from Genentech, Inc.
Other Metastatic Breast Cancer trials with similar outcome
A PHASE2 clinical study on Metastatic Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Genentech, Inc. and has accumulated 9 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.